Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases
Authors:
- 23 July 2008
- journal article
- research article
- Published by Springer Nature in Heart and Vessels
- Vol. 23 (4) , 249-256
Abstract
The development and progression of atherosclerosis comprises various processes, such as endothelial dysfunction, chronic inflammation, thrombus formation, and lipid profile modification. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that have pleiotropic effects in addition to cholesterol-lowering properties. However, the mechanisms of these effects are not completely understood. Here, we investigated whether atorvastatin affects the levels of malondialdehyde-modified low-density lipoprotein (MDALDL), an oxidized LDL, the proinflammatory cytokine interleukin-6 (IL-6), or platelet P-selectin, a marker of platelet activation, relative to that of LDL cholesterol (LDL-C). Forty-eight patients with coronary artery disease and hyperlipidemia were separated into two groups that were administered with (atorvastatin group) or without (control group) atorvastatin. The baseline MDA-LDL level in all participants significantly correlated with LDL-C (r = 0.71, P < 0.01) and apolipoprotein B levels (r = 0.66, P < 0.01). Atorvastatin (10 mg/day) significantly reduced the LDL-C level within 4 weeks and persisted for a further 8 weeks of administration. Atorvastatin also reduced the MDA-LDL level within 4 weeks and further reduced it over the next 8 weeks. Platelet P-selectin expression did not change until 4 weeks of administration and then significantly decreased at 12 weeks, whereas the IL-6 level was gradually, but not significantly, reduced at 12 weeks. In contrast, none of these parameters significantly changed in the control group within these time frames. The reduction (%) in IL-6 between 4 and 12 weeks after atorvastatin administration significantly correlated with that of MDALDL and of platelet P-selectin (r = 0.65, P < 0.05 and r = 0.70, P < 0.05, respectively). These results suggested that the positive effects of atorvastatin on the LDL-C oxidation, platelet activation and inflammation that are involved in atherosclerotic processes are exerted in concert after lowering LDL-C.Keywords
This publication has 59 references indexed in Scilit:
- Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery diseaseAtherosclerosis, 2005
- Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosisThe American Journal of Cardiology, 2004
- Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjectsInternational Journal of Cardiology, 2004
- Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectorisThe American Journal of Cardiology, 2004
- Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery AtherosclerosisCirculation, 2003
- Low-Density Lipoprotein-Induced Expression of Interleukin-6, a Marker of Human Mesangial Cell Inflammation: Effects of Oxidation and Modulation by LovastatinBiochemical and Biophysical Research Communications, 2000
- Absence of P-selectin delays fatty streak formation in mice.Journal of Clinical Investigation, 1997
- Mildly Oxidized LDL Induces Platelet Aggregation Through Activation of Phospholipase A2Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular DiseaseNew England Journal of Medicine, 1990
- Interleukin-6: An OverviewAnnual Review of Immunology, 1990